{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:38Z","timestamp":1792790498531,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["JCZRLH202600973"],"award-info":[{"award-number":["JCZRLH202600973"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"Youth Science Fund Project","doi-asserted-by":"publisher","award":["81901713"],"award-info":[{"award-number":["81901713"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04952-w","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:13:13Z","timestamp":1779383593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative safety and efficacy of hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy, with or without transarterial chemoembolization, in unresectable hepatocellular carcinoma: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ruibing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxv","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"3","key":"4952_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4952_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00000658-199503000-00012","volume":"221","author":"EC Lai","year":"1995","unstructured":"Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291\u20138.","journal-title":"Ann Surg"},{"key":"4952_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/BF01656375","volume":"6","author":"NW Lee","year":"1982","unstructured":"Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg. 1982;6:66\u201375.","journal-title":"World J Surg"},{"issue":"6","key":"4952_CR4","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365.","journal-title":"Hepatology"},{"issue":"3","key":"4952_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"4952_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-019-0782-x","volume":"12","author":"Z Yin","year":"2019","unstructured":"Yin Z, Dong C, Jiang K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 2019;12(1):101.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"4952_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/HEP.0000000000000513","volume":"81","author":"R Dhanasekaran","year":"2025","unstructured":"Dhanasekaran R, Suzuki H, Lemaitre L, et al. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. Hepatology. 2025;81(3):1038\u201357.","journal-title":"Hepatology"},{"key":"4952_CR8","doi-asserted-by":"crossref","unstructured":"Jiang P, Chen C, Tian J et al. Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis. Acad Radiol. 2024;S1076-6332(24)00710-4.","DOI":"10.37766\/inplasy2024.8.0012"},{"key":"4952_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/BF00402774","volume":"111","author":"R Bartkowski","year":"1986","unstructured":"Bartkowski R, Berger MR, Aguiar JL, et al. Experiments on the efficacy and toxicity of locoregional 25 chemotherapy of liver tumors with 5-fluoro-2\u2019-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Cancer Res Clin Oncol. 1986;111:42\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"21","key":"4952_CR10","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","volume":"21","author":"Y Chang","year":"2020","unstructured":"Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21):8165.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4952_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A review in hepatocellular carcinoma. Drugs. 2019;79(6):665\u201374.","journal-title":"Drugs"},{"issue":"5","key":"4952_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4952_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1566523220666200628014530","volume":"20","author":"CH Zhang","year":"2020","unstructured":"Zhang CH, Li M, Lin YP, Gao Q. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Curr Gene Ther. 2020;20(2):84\u201399.","journal-title":"Curr Gene Ther"},{"issue":"7","key":"4952_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2174\/1874467215666220103111009","volume":"15","author":"S Altaf","year":"2022","unstructured":"Altaf S, Saleem F, Sher AA, Ali A. Potential Therapeutic Strategies to Combat HCC. Curr Mol Pharmacol. 2022;15(7):929\u201342.","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"4952_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/1874467212666191113130312","volume":"13","author":"S Xiang","year":"2020","unstructured":"Xiang S, Shao X, Cao J, Yang B, He Q, Ying M. FAT10: Function and Relationship with Cancer. Curr Mol Pharmacol. 2020;13(3):182\u201391.","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"4952_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11547-024-01781-3","volume":"129","author":"N Jiang","year":"2024","unstructured":"Jiang N, Zhang Z, Yin X, et al. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Radiol Med. 2024;129(4):631\u201342.","journal-title":"Radiol Med"},{"key":"4952_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin cancer research: official J Am Association Cancer Res. 2013;19:1312\u20134.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"4952_CR18","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"4952_CR19","unstructured":"Rohan T, Uher M, Matkul\u010d\u00edk P, et al. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Klin Onkol. 2020;33(3):214\u20139."},{"issue":"3","key":"4952_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"key":"4952_CR21","doi-asserted-by":"publisher","first-page":"1298122","DOI":"10.3389\/fonc.2024.1298122","volume":"14","author":"Z Huang","year":"2024","unstructured":"Huang Z, Wu Z, Zhang L, et al. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study. Front Oncol. 2024;14:1298122.","journal-title":"Front Oncol"},{"key":"4952_CR22","doi-asserted-by":"publisher","first-page":"1421520","DOI":"10.3389\/fimmu.2024.1421520","volume":"15","author":"H Fang","year":"2024","unstructured":"Fang H, Ke Q, Wu S, et al. Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis. Front Immunol. 2024;15:1421520.","journal-title":"Front Immunol"},{"issue":"1","key":"4952_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers13010090","volume":"13","author":"G Cabibbo","year":"2020","unstructured":"Cabibbo G, Celsa C, Enea M, et al. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers (Basel). 2020;13(1):90.","journal-title":"Cancers (Basel)"},{"key":"4952_CR24","doi-asserted-by":"crossref","unstructured":"Kok PS, Yoon WH, Lord S et al. Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JCO Precis Oncol. 2021;5:PO.21.00108.","DOI":"10.1200\/PO.21.00108"},{"issue":"1","key":"4952_CR25","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/s41598-024-54945-6","volume":"14","author":"L Huang","year":"2024","unstructured":"Huang L, Kang D, Zhao C, et al. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Sci Rep. 2024;14(1):4327.","journal-title":"Sci Rep"},{"issue":"15","key":"4952_CR26","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3390\/cancers15153789","volume":"15","author":"Y Kawamura","year":"2023","unstructured":"Kawamura Y, Akuta N, Shindoh J, et al. Efficacy of the combination of systemic sequential therapy and locoregional therapy in the long-term survival of patients with BCLC stage C hepatocellular carcinoma. Cancers (Basel). 2023;15(15):3789.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4952_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","volume":"19","author":"RA Miksad","year":"2019","unstructured":"Miksad RA, Ogasawara S, Xia F, et al. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer. 2019;19(1):795.","journal-title":"BMC Cancer"},{"issue":"2","key":"4952_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.critrevonc.2010.07.019","volume":"79","author":"Z Sun","year":"2011","unstructured":"Sun Z, Li G, Ai X, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol. 2011;79(2):164\u201374.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04952-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:04:13Z","timestamp":1784073853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04952-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04952-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (approval number: TJ-IRB20230950). Informed consent for patients was waived by the ethics committee since the study adopted a retrospective design.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"448"}}